Denali Therapeutics Inc. (DNLI) |
|
23.04 1.13 (5.16%)
|
03-31 16:00 |
|
Open: |
22.1 |
Pre. Close: |
21.91 |
|
High:
|
23.11 |
Low:
|
21.96 |
|
Volume:
|
1,096,709 |
Market Cap:
|
3,149(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:18:05 PM |
|
Overall:
|
  |
| Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 30.01 One year: 32.86 |
| Support: |
Support1: 21.73 Support2: 18.08 |
| Resistance: |
Resistance1: 25.69 Resistance2: 28.13 |
| Pivot: |
23.11  |
| Moving Average: |
MA(5): 22.82 MA(20): 23.65
MA(100): 28.25 MA(250): 28.92 |
| MACD: |
MACD(12,26): -1.3 Signal(9): -1.4 |
| Stochastic oscillator: |
%K(14,3): 27.5 %D(3): 20.8 |
| RSI: |
RSI(14): 39.8 |
| 52-week: |
High: 39.43 Low: 20.23 |
| Average Vol(K): |
3-Month: 683 (K) 10-Days: 660 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ DNLI ] has closed above bottom band by 45.8%. Bollinger Bands are 62.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
23.32 - 23.44 |
23.44 - 23.53 |
|
Low:
|
21.44 - 21.59 |
21.59 - 21.71 |
|
Close:
|
21.7 - 21.93 |
21.93 - 22.11 |
|
Company Description |
|
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. |
Headline News |
Wed, 29 Mar 2023
Why Is Denali Therapeutics Inc. (DNLI) Down 16% Since Last Earnings Report? - Zacks Investment Research
Wed, 29 Mar 2023
Why Is Denali Therapeutics Inc. (DNLI) Down 16% Since Last Earnings Report? - Yahoo Finance
Fri, 24 Mar 2023
Jeff Bezos Stock Portfolio: 10 Companies and Startups - Yahoo Finance
Fri, 24 Mar 2023
Bank of New York Mellon Corp Acquires 27162 Shares of Denali ... - MarketBeat
Tue, 21 Mar 2023
Look Under The Hood: IYY Has 18% Upside - Nasdaq
Mon, 20 Mar 2023
Media mogul Rupert Murdoch engaged to Ann Lesley Smith - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
137 (M) |
| Shares Float |
110 (M) |
|
% Held by Insiders
|
14.8 (%) |
|
% Held by Institutions
|
78.9 (%) |
|
Shares Short
|
7,030 (K) |
|
Shares Short P.Month
|
7,400 (K) |
Stock Financials |
|
EPS
|
-2.58 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
7.67 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-314.2 |
|
Return on Assets (ttm)
|
-14.9 |
|
Return on Equity (ttm)
|
-32.6 |
|
Qtrly Rev. Growth
|
-17.8 |
|
Gross Profit (p.s.)
|
-1.84 |
|
Sales Per Share
|
0.79 |
|
EBITDA (p.s.)
|
-2.42 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-245 (M) |
|
Levered Free Cash Flow
|
-141 (M) |
Stock Valuations |
|
PE Ratio
|
-8.94 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
3 |
|
Price to Sales
|
29.03 |
|
Price to Cash Flow
|
-12.87 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
